AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7726087
Drug: Delayed imaging
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed imaging after injection of standard contrast dose
Trial: 7726087
Drug: Delayed imaging
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed imaging after injection of higher contrast dose
Trial: 7726087
Drug: Cumulative triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative triple dose (0.3 mmol/kg)
Trial: 25774878
Drug: Computer self-administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer self-administration of the CRAFFT screening protocol
Trial: 22448928
Drug: Risperidone long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone long-acting injection (RLAI)
Trial: 16735934
Drug: raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: raloxifene 60 mg/day
Trial: 1946889
Drug: Beta-adrenergic blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic blockers (15 subjects)
Trial: 30868491
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for 3 months
Trial: 14576501
Drug: Imipenem 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem 0.5 g q.i.d. intravenously
Trial: 14576501
Drug: Meropenem 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 0.5 g t.i.d. intravenously
Trial: 10409530
Drug: atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 50 mg once daily
Trial: 1345218
Drug: co‐amiloride 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co‐amiloride 25 mg + amiloride 5 mg once daily
Trial: 18818847
Drug: In-shower body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-shower body lotion product form
Trial: 7595716
Drug: GM‐CSF treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF treatment
Trial: 31950267
Drug: Propofol (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (group P) at Ce of 4 μg/ml
Trial: 31950267
Drug: Propofol (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (group P) at Ce of 2 or 3 μg/ml
Trial: 27346437
Drug: Irbesartan 150-300
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150-300 mg/day
Trial: 26447156
Drug: Choline supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline supplementation (500 mg daily for 9 months)
Trial: 15330679
Drug: Estradiol/levonorgestrel (4.4/1.39
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol/levonorgestrel (4.4/1.39 [approved dosage], 4.4/2.74, and 4.5/3.75mg)
Trial: 11130523
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (placebo-controlled trials)
Trial: 11130523
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists (placebo-controlled trials)
Trial: 8255408
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of the partial 5‐HT1A agonist ipsapirone
Trial: 20961269
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg/day)
Trial: 30019249
Drug: Minodronate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minodronate (1 mg/day or 50 mg/4 weeks)
Trial: 15357646
Drug: Interferon-beta-1a 24
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-beta-1a 24 MIU (88 microg) administered three times weekly
Trial: 15357646
Drug: Interferon-beta-1a 12
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-beta-1a 12 MIU (44 microg) administered daily
Trial: 15357646
Drug: Interferon-beta-1a 24
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-beta-1a 24 MIU (88 microg) administered daily
Trial: 9833848
Drug: Abacavir-ZDV combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacavir-ZDV combination therapy (600 mg ZDV)
Trial: 18712029
Drug: Petrolatum ointment
RxNorm normalized name: GERI PROTECT Petrolatum Ointment
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Petrolatum ointment
Trial: 25375836
Drug: Escitalopram (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (5-20 mg/d)
Trial: 23815124
Drug: Nitroglycerin 0.4%
RxNorm normalized name: NITROGLYCERIN 0.4% OINT,RTL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin 0.4% ointment (375 mg applied anally every 12 hours for 21 days)
Trial: 23815124
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment (375 mg applied anally every 12 hours for 21 days)
Trial: 16883264
Drug: Quinapril (Q)
DrugBank: Quinapril (DB00881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinapril (Q) at an average dose of 13 mg/day (n=28)
Trial: 16883264
Drug: Valsartan (V)
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan (V) at a dose of 121 mg/day (n=26)
Trial: 16883264
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Quinapril and Valsartan (Q+V) at doses of 12 mg/day and 78 mg/day respectively (n=26)
Trial: 9240579
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation >8000 IU daily
Trial: 9240579
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation >10000 IU daily
Trial: 3623736
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg every 12 hours for 7 days
Trial: 3623736
Drug: Nalidixic acid
RxNorm normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalidixic acid 500 mg every 8 hours for 7 days
Trial: 27774990
Drug: Pomalidomide (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide (both doses)
Trial: 30539861
Drug: SOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOX regimen chemotherapy alone
Trial: 30539861
Drug: Endostar continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endostar continuous intravenous infusion combined with SOX regimen chemotherapy
Trial: 23040422
Drug: Screening followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening followed by intensive multifactorial treatment for people diagnosed with diabetes (n=15)
Trial: 31162017
Drug: Doxycycline treatment
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline treatment
Trial: 30207587
Drug: Namilumab (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Namilumab (20, 50, 80, and 150 mg via subcutaneous injection)
Trial: 28884242
Drug: Low-dose BoNT-A
RxNorm normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose BoNT-A injections at the pretarsal (PT) portion
Trial: 28884242
Drug: Low-dose BoNT-A
RxNorm normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose BoNT-A injections at the preseptal (PS) portion
Trial: 25778933
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose combination (paracetamol 500 mg and ibuprofen 150 mg)
Trial: 25778933
Drug: All combination
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All combination doses
Trial: 21748479
Drug: Heavyweight polypropylene
RxNorm normalized name: polypropylene (30000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavyweight polypropylene mesh (HWM) (105 g/m(2))
Trial: 21748479
Drug: Lightweight polypropylene
RxNorm normalized name: polypropylene (30000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lightweight polypropylene mesh (LWM) (28 g/m(2))
Trial: 10955702
Drug: L-NAME
RxNorm normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME
Trial: 7001038
Drug: Fixed drug
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed drug combination of chloroquine and paracetamol (single dose)
Trial: 7001038
Drug: Chloroquine and
RxNorm normalized name: chloroquine and proguanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine and paracetamol given as separate tablets (extended over 3 days or longer)
Trial: 6343259
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg twice daily
Trial: 10442510
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg once daily
Trial: 6343259
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg once daily
Trial: 6343259
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg once daily
Trial: 17566314
Drug: Amlodipine/benazepril 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/benazepril 10/20 mg/day
Trial: 17566314
Drug: Amlodipine/benazepril 10/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/benazepril 10/40 mg/day
Trial: 22571394
Drug: Benazepril 40
RxNorm normalized name: benazepril 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 40 mg/day
Trial: 12038945
Drug: 4-mg nicotine
RxNorm normalized name: nicotine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mg nicotine lozenge
Trial: 12038945
Drug: 2-mg nicotine
RxNorm normalized name: nicotine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mg nicotine lozenge
Trial: 12456454
Drug: ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 8 mg IV
Trial: 31264757
Drug: Efpeglenatide 4
RxNorm normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efpeglenatide 4 mg once weekly
Trial: 31264757
Drug: Efpeglenatide 8
RxNorm normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efpeglenatide 8 mg once every 2 weeks
Trial: 20370845
Drug: Oxycodone prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone prolonged release/naloxone prolonged release
Trial: 17547746
Drug: Long-acting corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting corticosteroid injection
Trial: 231374
Drug: Intramuscular ACTH
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular ACTH (0.5 mg) for 4 days
Trial: 31173422
Drug: Vaccine-and-behaviour-change intervention
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-and-behaviour-change intervention (VBC)
Trial: 31173422
Drug: Vaccine-only (V)
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-only (V)
Trial: 29092012
Drug: NEPA (netupitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEPA (netupitant 300 mg and palonosetron 0.50 mg)
Trial: 27885469
Drug: Oral PALO
RxNorm normalized name: palo verde pollen extract
DrugBank: Parkinsonia florida pollen (DB11006)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PALO (palonosetron 0.50 mg)
Trial: 1396064
Drug: Tramadol HCL
RxNorm normalized name: tramadol HCl
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol HCL capsule (THC)
Trial: 4079660
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered intranasally, double-blind, prior to ethanol ingestion
Trial: 12752346
Drug: Famotidine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 1.0 mg/kg
Trial: 11069316
Drug: ASA 650
RxNorm normalized name: ASA 650 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 650 mg q. d.s.
Trial: 9014908
Drug: Intravenous Immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Immunoglobulin (IVIg)
Trial: 10225757
Drug: Plasma Exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma Exchange followed by Intravenous Immunoglobulin (PE + IVIg)
Trial: 8038352
Drug: famotidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine (20 mg b.d.)
Trial: 8038352
Drug: cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine (400 mg b.d.)
Trial: 8038352
Drug: ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine (150 mg b.d.)
Trial: 2902494
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg twice daily for two years or until death
Trial: 22289235
Drug: Full kinematic
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full kinematic chain manual and manipulative therapy (MMT) plus exercise
Trial: 22289235
Drug: Targeted hip
RxNorm normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted hip manual and manipulative therapy (MMT) plus exercise
Trial: 19057270
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/d orally until disease progression or intolerable toxicity
Trial: 15909433
Drug: Topical gentamicin
RxNorm normalized name: gentamicin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gentamicin
Trial: 12824811
Drug: Alcohol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.75 g/kg mixed with diet soda)
Trial: 10586830
Drug: Chemoradiation (radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation (radiotherapy combined with systemic chemotherapy)
Trial: 25087600
Drug: Agomelatine (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine (25-50 mg/day)
Trial: 14744167
Drug: Escitalopram (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10-20 mg/day)
Trial: 18322633
Drug: Fluticasone 250
RxNorm normalized name: FLUTICASONE 250MCG/BLSTR PO INH ROTADISK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone 250 mcg/day
Trial: 15731291
Drug: Etoricoxib 90
RxNorm normalized name: etoricoxib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 90 mg or 120 mg once a day, Naproxen 500 mg twice daily
Trial: 7485925
Drug: Zolpidem 8.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 8.03 mg/placebo
Trial: 7485925
Drug: Phenobarbital 100
RxNorm normalized name: phenobarbital 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital 100 mg/promethazine 50 mg
Trial: 7485925
Drug: Phenobarbital 100
RxNorm normalized name: phenobarbital 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital 100 mg/placebo
Trial: 8398960
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg morphine injected intravenously
Trial: 8398960
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of physiologic saline diluted to 5 ml with 5% glucose (Control)
Trial: 12186344
Drug: Frialit-2 implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frialit-2 implants used in bone reconstruction
Trial: 10687523
Drug: Flurbiprofen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (100 mg loading dose and then 50 mg every 6 h)
Trial: 8579082
Drug: Antibiotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics plus rh‐GMCSF (3 micrograms/kg per day i.v.)
Trial: 8579082
Drug: Antibiotics alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics alone (ticarcillin‐clavulanate + netilmicin)
Trial: 8579082
Drug: Antibiotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics plus rh‐GMCSF
Trial: 1937326
Drug: cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cefuroxime axetil 2 x 500 mg/d
Trial: 26359076
Drug: Patient controlled
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controlled intravenous analgesia (PCIA)
Trial: 26537182
Drug: Metformin (females)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (females)
Trial: 26537182
Drug: Metformin (males)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (males)
Trial: 24091128
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2) plus Epirubicin (75 mg/m2) plus Bevacizumab (15 mg/kg) every 3 weeks for up to 9 cycles followed by Bevacizumab (15 mg/kg) until disease progression
Trial: 24091128
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2) plus Epirubicin (75 mg/m2) plus Bevacizumab (15 mg/kg)
Trial: 21846852
Drug: Pegloticase 8
RxNorm normalized name: pegloticase 8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegloticase 8 mg biweekly (every 2 weeks)
Trial: 21846852
Drug: Pegloticase alternating
RxNorm normalized name: Pegloticase
DrugBank: Pegloticase (DB09208)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegloticase alternating with placebo (monthly treatment group)
Trial: 15480643
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy at energy level E2=0.44 mJ/mm2
Trial: 11738123
Drug: 3-hydroxy-3-methyl-glutaryl coenzyme
RxNorm normalized name: 2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor (pravastatin)
Trial: 9740604
Drug: Nitrendipine monotherapy
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine monotherapy (average dose 23.4 mg/d)
Trial: 26730183
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg
Trial: 25458157
Drug: Umeclidinium/vilanterol (UMEC/VI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg
Trial: 18344850
Drug: McKenzie therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: McKenzie therapy
Trial: 25159291
Drug: Electrophysical agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrophysical agents
Trial: 10919680
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate HFA 134a pMDIs (400, 1000, and 2000 microg doses)
Trial: 8828766
Drug: Heparin-coated CPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated CPB system (HC group)
Trial: 8828766
Drug: Heparin-coated oxygenator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated oxygenator and uncoated CPB circuit (HO group)
Trial: 3993041
Drug: iodine therapy
RxNorm normalized name: IODINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iodine therapy with iodine brine
Trial: 3993041
Drug: remedial exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remedial exercise plus iodine brine therapy
Trial: 29338568
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose infusion (TDI) of low-molecular weight (LMW) iron dextran (group B)
Trial: 22456294
Drug: Vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 50 mg administered immediately before meals
Trial: 22456294
Drug: Vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 50 mg (both regimens)
Trial: 12642201
Drug: Combination program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination program or information alone
Trial: 10573067
Drug: 100 microg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg/day of G-CSF
Trial: 1888645
Drug: Plain aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain aspirin 600 mg four times daily
Trial: 1888645
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin 300 mg daily
Trial: 1888645
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin 600 mg four times daily
Trial: 20217051
Drug: Speech preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech preparation session
Trial: 15101858
Drug: Stellate ganglion
RxNorm normalized name: Mastocarpus stellatus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stellate ganglion block (SGB) with 10 ml of 1% lidocaine